Scholarlink

Purpose <p>This study seeks to explore whether intra-wound vancomycin powder (IVP) is a cost-effective adjunct to standard of care (SOC) in patients undergoing total joint arthroplasty (TJA) from a US payor perspective.</p> Methods <p>A decision-analytic model in the form of a decision tree was developed to compare the cost and outcomes of IVP with those of SOC in preventing periprosthetic joint infections (PJI) in TJA patients. The base case analysis assumes a hypothetical practice with an equal volume (50/50) of THA and TKA procedures in both the IVP + SOC and the SOC arm. Cost and clinical effectiveness data were obtained from published literature. Sensitivity and threshold analyses were used to estimate how changing inputs would impact the cost-effectiveness of IVP.</p> Results <p>Deterministic results found that in the base case model, IVP as an adjunct to SOC generates a cost saving of $260.38/patient. In scenario analysis, where THA and TKA procedures were separated, the estimated cost saving was $241.50/patient and $279.27/patient, respectively. Break-even analysis showed that the cost of IVP per patient would need to be $244.82-$282.59, or the PJI relative risk (RR) be approximately 0.99. Probabilistic analysis found IVP + SOC was cost-saving in 99.26% of the 10,000 iterations in the base case model.</p> Conclusion <p>Applying local vancomycin as an adjunct to SOC in primary TJA is not just cost effective, but cost-saving in reducing PJIs, saving an average of $260.38/patient. Depending on individual institution/practice infection rates&#xa0;and revision surgery costs, local vancomycin administration for primary TJA should be considered.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intra-wound vancomycin powder is cost-saving in primary total hip and knee arthroplasty

  • 期刊论文

  • 发表日期：

    2025年3月19日

查看全文
  • Darius L. Lameire,
  • Neil Askew,
  • Iqbal Multani,
  • Graeme Hoit,
  • Amir Khoshbin,
  • Leo M. Nherera,
  • Amit Atrey

摘要

Purpose

This study seeks to explore whether intra-wound vancomycin powder (IVP) is a cost-effective adjunct to standard of care (SOC) in patients undergoing total joint arthroplasty (TJA) from a US payor perspective.

Methods

A decision-analytic model in the form of a decision tree was developed to compare the cost and outcomes of IVP with those of SOC in preventing periprosthetic joint infections (PJI) in TJA patients. The base case analysis assumes a hypothetical practice with an equal volume (50/50) of THA and TKA procedures in both the IVP + SOC and the SOC arm. Cost and clinical effectiveness data were obtained from published literature. Sensitivity and threshold analyses were used to estimate how changing inputs would impact the cost-effectiveness of IVP.

Results

Deterministic results found that in the base case model, IVP as an adjunct to SOC generates a cost saving of $260.38/patient. In scenario analysis, where THA and TKA procedures were separated, the estimated cost saving was $241.50/patient and $279.27/patient, respectively. Break-even analysis showed that the cost of IVP per patient would need to be $244.82-$282.59, or the PJI relative risk (RR) be approximately 0.99. Probabilistic analysis found IVP + SOC was cost-saving in 99.26% of the 10,000 iterations in the base case model.

Conclusion

Applying local vancomycin as an adjunct to SOC in primary TJA is not just cost effective, but cost-saving in reducing PJIs, saving an average of $260.38/patient. Depending on individual institution/practice infection rates and revision surgery costs, local vancomycin administration for primary TJA should be considered.